Trials / Unknown
UnknownNCT03274479
PBF-1129 in Patients With NSCLC
Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Palobiofarma SL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PBF-1129 | PBF-1129 once a day by oral administration |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2024-05-01
- Completion
- 2024-08-01
- First posted
- 2017-09-07
- Last updated
- 2024-02-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03274479. Inclusion in this directory is not an endorsement.